Company Adds Mark A. Rothera as Global President

CAMBRIDGE, Mass., May 26, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of novel therapies for patients with debilitating rare diseases, today announced the primary endpoint was achieved in the

CAMBRIDGE, Mass., April 14, 2011 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc . (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, today acknowledged the publication of the National Lipid

Conference Call to be Held at 8:00 a.m. EST Today

CAMBRIDGE, Mass., Dec. 6, 2011 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, announced the appointment of Anne Marie Cook as Senior Vice

--Strategic Merger Creates Well-Capitalized, Global Biopharmaceutical Organization with Diverse Portfolio of Two Commercialized Rare Disease Programs and a Phase 3 Ready Ultra-Orphan Development Program Addressing Significant Unmet Medical Need-- --Broad-Based Investor Syndicate to Vote in Favor of

Aegerion Pharmaceuticals and QLT Inc. Agree to Strategic Merger   --Strategic Merger Creates Well-Capitalized, Global Biopharmaceutical Organization with Diverse Portfolio of Two Commercialized Rare Disease Programs and a Phase 3 Ready Ultra-Orphan Development Program Addressing Significant Unmet

Results Will Be Presented Today At AHA Conference in Orlando, Florida

CAMBRIDGE, Mass., July 21, 2011 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, announced today the appointment of Paul G.

CAMBRIDGE, Mass., April 19, 2011 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc.  (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, announced today the appointment of Sol J.